AGP Picks
View all

California Health Watch
Provided by AGP

California Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

Press releases published on April 27, 2026

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Apr. 27, 2026

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Indeterminate GlobeNewswire
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
Apr. 27, 2026

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Indeterminate GlobeNewswire
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Apr. 27, 2026

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Indeterminate GlobeNewswire
NIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product Innovation
Apr. 27, 2026

NIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product Innovation

Indeterminate GlobeNewswire
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Apr. 27, 2026

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Indeterminate GlobeNewswire
Weight Watchers Announces Actions to Utilize Up to $40 million to Pay Down Debt
Apr. 27, 2026

Weight Watchers Announces Actions to Utilize Up to $40 million to Pay Down Debt

Indeterminate GlobeNewswire
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
Apr. 27, 2026

HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors

Indeterminate GlobeNewswire
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
Apr. 27, 2026

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

Indeterminate GlobeNewswire
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
Apr. 27, 2026

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

Indeterminate GlobeNewswire
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Apr. 27, 2026

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

Indeterminate GlobeNewswire
Suja Life Announces Launch of Initial Public Offering
Apr. 27, 2026

Suja Life Announces Launch of Initial Public Offering

Indeterminate GlobeNewswire
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
Apr. 27, 2026

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Indeterminate GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Apr. 27, 2026

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Indeterminate GlobeNewswire
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Apr. 27, 2026

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Indeterminate GlobeNewswire
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
Apr. 27, 2026

Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma

Indeterminate GlobeNewswire
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
Apr. 27, 2026

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Indeterminate GlobeNewswire
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Apr. 27, 2026

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Indeterminate GlobeNewswire
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Apr. 27, 2026

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Indeterminate GlobeNewswire
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
Apr. 27, 2026

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

Indeterminate GlobeNewswire
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Apr. 27, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Indeterminate GlobeNewswire
Show More

Share this page:

Sign up for:

California Health Watch

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.